BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway. Announced encouraging preliminary ...

As bars and restaurants across the globe contemplate how to safely serve diners during the pandemic, many establishments are seeking ways to reduce the number of touchpoints between servers and guests ...

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...

DoorDash is acquiring Bbot, a hospitality technology startup. The acquisition will offer merchants more solutions for their in-store and online channels, including in-store digital ordering and ...

Bbot Inc. a restaurant and hospitality tech startup focused on simplifying and improving the ordering and payment process, announced the closing of a $4 million seed extension funding round. Rally ...

Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed ...

Bbot, the hospitality tech provider that focuses on digital ordering and payments for restaurants, has agreed to be acquired by DoorDash to expand its service offering to merchants. The terms of the ...

Steve Simoni wasn't planning on starting a software company. Instead, he and his colleagues were intent on building a robot that would make it easier for them to get drinks at a bar. Their original ...

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs Announced publication in Cancer Discovery highlighting preclinical data demonstrating ...

BBO-8520 monotherapy in patients with KRAS G12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients ...